Mark Chappell to Lisinopril
This is a "connection" page, showing publications Mark Chappell has written about Lisinopril.
Connection Strength
0.558
-
Ferrario CM, Jessup J, Gallagher PE, Averill DB, Brosnihan KB, Ann Tallant E, Smith RD, Chappell MC. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int. 2005 Nov; 68(5):2189-96.
Score: 0.274
-
Westwood BM, Chappell MC. Divergent pathways for the angiotensin-(1-12) metabolism in the rat circulation and kidney. Peptides. 2012 Jun; 35(2):190-5.
Score: 0.107
-
Jessup JA, Westwood BM, Chappell MC, Groban L. Dual ACE-inhibition and AT1 receptor antagonism improves ventricular lusitropy without affecting cardiac fibrosis in the congenic mRen2.Lewis rat. Ther Adv Cardiovasc Dis. 2009 Aug; 3(4):245-57.
Score: 0.088
-
Ferrario CM, Smith RD, Brosnihan B, Chappell MC, Campese VM, Vesterqvist O, Liao WC, Ruddy MC, Grim CE. Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension. Am J Hypertens. 2002 Jun; 15(6):557-64.
Score: 0.054
-
Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Chappell MC, Ferrario CM. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. . 2006 Nov; 291(5):H2166-72.
Score: 0.018
-
Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005 May 24; 111(20):2605-10.
Score: 0.017